Relating to warning labels for opioid prescription drugs.
Relating to warning labels for opioid prescription drugs.
Relating to an acknowledgment on receipt of an opioid prescription drug.
Relating to distinctive packaging for opioid prescription drugs.
Relating to a pilot program for the safe disposal of prescription drugs, including controlled substance prescription drugs.
Relating to health benefit plan coverage of prescription drugs for serious mental illnesses and opioid and substance use disorders.
Relating to the maintenance, administration, and disposal of opioid antagonists on public and private school campuses and to the permissible uses of money appropriated to a state agency from the opioid abatement account.
Relating to the maintenance, administration, and disposal of opioid antagonists on public and private school campuses and to the permissible uses of money appropriated to a state agency from the opioid abatement account.
Relating to promoting, prescribing, administering, or dispensing prescription drugs for off-label use.
Relating to patient access to prescription drugs for off-label use for COVID-19 treatment.